Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Regeneus Ltd. (AU:CMB)
ASX:CMB
Holding AU:CMB?
Track your performance easily
CMB Stock Chart & Stats
Day’s RangeAU$0 - AU$0
52-Week RangeAU$0.30 - AU$1.60
Previous CloseAU$0.39
Volume0.00
Average Volume (3M)4.90K
Market Cap
AU$5.18M
Enterprise ValueAU$6.02M
Total Cash (Recent Filing)AU$164.40K
Total Debt (Recent Filing)AU$1.01M
Price to Earnings (P/E)―
Beta-6.17
Next Earnings
Feb 27, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.54
Shares OutstandingN/A
10 Day Avg. Volume9,900
30 Day Avg. Volume4,898
Standard Deviation0.24
R-Squared0.04
Alpha-0.01
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)16.04
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Regeneus Ltd. News
PremiumCompany Announcements
Cambium Bio Gains FDA Fast Track for Eye TreatmentPremiumCompany Announcements
Cambium Bio Secures A$3M for Clinical Advancements
PremiumCompany Announcements
Cambium Bio Limited Initiates Trading Halt on ASX
PremiumCompany Announcements
Cambium Bio Limited’s AGM Results and Strategic Moves
PremiumCompany Announcements
Cambium Bio Limited Advances Regenerative Medicine Platform
PremiumCompany Announcements
Cambium Bio Limited to Issue New Securities
PremiumCompany Announcements
Cambium Bio Limited Strengthens Board with New AppointmentPremiumCompany Announcements
Cambium Bio Advances Elate Ocular Development Amid Funding EffortsCMB FAQ
What was Regeneus Ltd.’s price range in the past 12 months?
Regeneus Ltd. lowest share price was AU$0.30 and its highest was AU$1.60 in the past 12 months.
What is Regeneus Ltd.’s market cap?
Currently, no data Available
When is Regeneus Ltd.’s upcoming earnings report date?
Regeneus Ltd.’s upcoming earnings report date is Feb 27, 2025 which is in 66 days.
How were Regeneus Ltd.’s earnings last quarter?
Regeneus Ltd. released its earnings results on Aug 30, 2024. The company reported -AU$0.177 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.177.
Is Regeneus Ltd. overvalued?
According to Wall Street analysts Regeneus Ltd.’s price is currently Overvalued.
Does Regeneus Ltd. pay dividends?
Regeneus Ltd. does not currently pay dividends.
What is Regeneus Ltd.’s EPS estimate?
Regeneus Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Regeneus Ltd. have?
Regeneus Ltd. has 13,280,389 shares outstanding.
What happened to Regeneus Ltd.’s price movement after its last earnings report?
Regeneus Ltd. reported an EPS of -AU$0.177 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Regeneus Ltd.?
Currently, no hedge funds are holding shares in AU:CMB
---
Regeneus Ltd. Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Fundamentals
Return on Equity
-469.28%
Trailing 12-Months
Asset Growth
690.69%
Trailing 12-Months
Company Description
Regeneus Ltd.
Regeneus Ltd clinical-stage regenerative medicine company. It mainly develops a portfolio of cell-based therapies to address significant unmet medical needs in the human and animal health markets with a focus on osteoarthritis and other musculoskeletal disorders, oncology and dermatology diseases. The company uses stem cell and immuno-oncology technologies to develop cell-based therapies. Its product pipeline consists of two platform technologies, Progenza and Sygenus, across three target therapeutic areas namely osteoarthritis, neuropathic pain, and skin wound healing.
---
Technical Analysis
PYC Therapeutics Limited
―
Race Oncology Ltd.
―
Cryosite Limited
―
Botanix Pharmaceuticals Limited
―
---